EUVIMEDScopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Incretins and cardiovascular disease: to the heart of type 2 diabetes?

Anna Solini, Domenico Tricò, Stefano Del Prato

Diabetologia · 2023-10 · 66 (10) · 1820-1831

DOI: 10.1007/s00125-023-05973-w ↗

At a glance

Übersichtsarbeit in Diabetologia, published online on 2023-08-05. Written by Anna Solini and 2 co-authors. Institution: Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy. Major MEDLINE topics: Diabetes Mellitus, Type 2, Cardiovascular Diseases. Cited 33 times so far (Crossref); 96 references. The full text is freely available (open access, CC BY 4.0). Funded by: Università di Pisa.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Major cardiovascular outcome trials and real-life observations have proven that glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), regardless of structural GLP-1 homology, exert clinically relevant cardiovascular protection. GLP-1RAs provide cardioprotective benefits through glycaemic and non-glycaemic effects, including improved insulin secretion and action, body-weight loss, blood-pressure lowering and improved lipid profile, as well as via direct effects on the heart and vasculature. These actions are likely combined with anti-inflammatory and antioxidant properties that translate into robust and consistent reductions in atherothrombotic events, particularly in people with type 2 diabetes and established atherosclerotic CVD. GLP-1RAs may also have an impact on obesity and chronic kidney disease, conditions for which cardiovascular risk-reducing options are limited. The available evidence has prompted professional and medical societies to recommend GLP-1RAs for mitigation of the cardiovascular risk in people with type 2 diabetes. This review summarises the clinical evidence for cardiovascular protection with use of GLP-1RAs and the main mechanisms underlying this effect. Moreover, it looks into how the availability of upcoming dual and triple incretin receptor agonists might expand the possibility for cardiovascular protection in people with type 2 diabetes. Graphical Abstract

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Cardiovascular DiseasesHumansIncretinsHypoglycemic AgentsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor Agonists

Author keywords

Cardiovascular diseasesDiabetes mellitus, type 2GlucagonGlucagon-like peptide-1Glucose-dependent insulinotropic polypeptideHeart failureIncretinsReview

Substances

IncretinsHypoglycemic AgentsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor Agonists

Authors and institutions

  • Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.
  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. stefano.delprato@unipi.it.
  • Interdisciplinary Research Center "Health Science", Sant'Anna School of Advanced Studies, Pisa, Italy. stefano.delprato@unipi.it.

Funding

  • Università di Pisa

Cite

APA

Solini, A., Tricò, D., & Del Prato, S. (2023). Incretins and cardiovascular disease: to the heart of type 2 diabetes?. Diabetologia, 66(10), 1820-1831. https://doi.org/10.1007/s00125-023-05973-w

Vancouver

Solini A, Tricò D, Del Prato S. Incretins and cardiovascular disease: to the heart of type 2 diabetes?. Diabetologia. 2023;66(10):1820-1831. doi:10.1007/s00125-023-05973-w

BibTeX
@article{Solini2023,
  author = {Solini, Anna and Tricò, Domenico and Del Prato, Stefano},
  title = {Incretins and cardiovascular disease: to the heart of type 2 diabetes?},
  journal = {Diabetologia},
  year = {2023},
  volume = {66},
  number = {10},
  pages = {1820--1831},
  doi = {10.1007/s00125-023-05973-w}
}
Start for free →